Compare ConocoPhillips (COP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Incyte Corporation — how do they compare? ConocoPhillips trades at $112 (market cap $136.29B), while Incyte Corporation trades at $112.62 (market cap $22.95B). The key difference: ConocoPhillips is far larger — about 5.9× Incyte Corporation's market cap, and ConocoPhillips pays a 3% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| COP | INCY | |
|---|---|---|
Market Cap | $136.29B | $22.95B |
Sector | Energy | Health |
52-Week High | $133.80 | $118.52 |
52-Week Low | $85.66 | $67.38 |
Enterprise Value | $153.25B | $18.97B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
